AstraZeneca (LON:AZN) Receives “Buy” Rating from Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by research analysts at Shore Capital in a research report issued to clients and investors on Friday,Digital Look reports.

Other analysts have also issued research reports about the company. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.80) price objective on shares of AstraZeneca in a research note on Monday, January 27th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of GBX 7,542.80 ($97.20).

AstraZeneca Price Performance

LON:AZN opened at £119.58 ($154.10) on Friday. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The stock’s 50 day moving average price is £112.76 and its two-hundred day moving average price is £114.26. The firm has a market capitalization of £230.08 billion, a price-to-earnings ratio of 32.78, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,670 ($124.61) and a 12-month high of £133.88 ($172.53).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.